Preclinical colitis models: KPV reduces mucosal inflammation in preclinical colitis models, with demonstrated reductions in TNF-, IL-6, and other pro-inflammatory markers
Each component is used in controlled laboratory settings: BPC-157 (10mg): A peptide fragment derived from a protein associated with gastric secretions, utilised in research involving peptide structure, signalling pathways, and experimental biological models
A phase I safety study in healthy adults confirmed that subcutaneous MOTS-c injections at doses up to 10 mg produced no serious adverse events, with a pharmacokinetic profile supporting once-daily or every-other-day dosing [3]
No lifestyle intervention was prescribed
Int J Res Rev 9:308317 Park HJ, Lee YJ, Ryu HK, Kim MH, Chung HW, Kim WY (2008) A randomized double-blind, placebo-controlled study to establish the effects of spirulina in elderly Koreans